Evidence map›Paper›PMID 19604271›Full record

ArticleClinical and experimental immunology2009

Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.

L Zhao, K Xiao, H Wang, Z Wang, L Sun, F Zhang, X Zhang, F Tang, W He

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04273529 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study

TypeinterventionalSponsorFirst Affiliated Hospital of Wenzhou Medical UniversityRan2020 to 2020Enrolled100ConditionsCOVID-19 ThalidomideArmsthalidomide, placebo
NCT04273581 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study

TypeinterventionalSponsorFirst Affiliated Hospital of Wenzhou Medical UniversityRan2020 to 2020Enrolled40ConditionsCOVID-19 ThalidomideArmsplacebo, Thalidomide
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Interstitial lung disease in systemic sclerosis: where do we stand?European respiratory review : an official journal of the European Respiratory Society · 2015
    Review
  5. Article
  6. The mighty fibroblast and its utility in scleroderma research.Journal of scleroderma and related disorders
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

L ZhaoDepartment of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
K Xiao
H Wang
Z Wang
L Sun
F Zhang
X Zhang
F Tang
W He
Chinese Academy of Medical Sciences & Peking Union Medical College · CNPeking Union Medical College Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to investigate the effects of thalidomide (THD) on interstitial lung fibrosis (ILF). In vitro, human fetal lung fibroblast (HFL-F) to myofibroblast (MF) trans-differentiation was induced by transforming growth factor (TGF)-beta1. The effects of THD on trans-differentiation process or differentiated MF were evaluated by measuring hydroxyproline (HYP) content by alkaline hydrolysis colorimetry, alpha-smooth muscle actin (alpha-SMA) protein by Western blot and alpha-SMA and pro-collagen III mRNA expressions by semi-quantitative reverse transcription-polymerase chain reaction; in vivo, a mouse model of ILF was generated by daily subcutaneous injection of bleomycin (BLM) in female C3H mice. Gastric perfusion of THD began 1 week prior to injection and lasted for 8 weeks. Lung specimens were harvested at different time-points (1, 4, 6 and 8 weeks) for pathology and immunohistochemistry examination. The HYP content, alpha-SMA and pro-collagen III mRNA expressions were also assessed. THD inhibited the up-regulation of HYP protein, pro-collagen III mRNA and alpha-SMA protein induced by TGF-beta1 in HFL-F cells, and additionally inhibited pro-collagen III mRNA expression on trans-differentiated MF. THD reduced HYP synthesis in the lung tissues of BLM-treated mice at week 4, and slightly reduced the numbers of alpha-SMA-positive cells. THD had an effect on ILF models both in vitro and in vivo.

Indexed as

ActinsAnimalsBleomycinBlotting, WesternCell DifferentiationCells, CulturedCollagen Type IIIFemaleFibroblastsHumansHydroxyprolineImmunohistochemistryImmunosuppressive AgentsLung Diseases, InterstitialMiceMice, Inbred StrainsActinsBleomycinCollagen Type IIIHydroxyprolineImmunosuppressive AgentsRNA, MessengerThalidomideTransforming Growth Factor beta1

Identifiers

PMID19604271
PMCPMC2730857
OpenAlexW2085809608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.